Table 1.
Baseline characteristics of patients in an uncomplicated or complicated stage of disease at day of positive SARS-CoV-2 detection
| Total | Uncomplicated clinical stage at day of positive SARS-CoV-2 detection | Complicated clinical stage at day of positive SARS-CoV-2 detection | |
|---|---|---|---|
| Included cases | 2155 | 65% (1400/2155) | 35% (755/2155) |
| Age (years) | |||
| ≤ 14 | 1.2% (26/2155) | 1.6% (23/1400) | 0.4% (3/755) |
| 15–25 | 2.7% (59/2155) | 4.0% (56/1400) | 0.4% (3/755) |
| 26–45 | 14.7% (317/2155) | 18.0% (252/1400) | 8.6% (65/755) |
| 46–65 | 34.4% (741/2155) | 34.5% (483/1400) | 34.2% (258/755) |
| 66–85 | 39.6% (500/2155) | 35.7% (500/1400) | 46.8% (353/755) |
| > 85 | 7.4% (159/2155) | 6.1% (86/1400) | 9.7% (73/755) |
| Sex | |||
| Female | 40.3% (868/2155) | 42.2% (591/1182) | 36.7% (277/554) |
| Male | 59.7% (1287/2155) | 57.8% (809/1400) | 63.3% (478/956) |
| Body mass index (kg/m2) | |||
| < 18.5 | 3.0% (36/1187) | 3.3% (24/724) | 2.6% (12/463) |
| 18.5–24.9 | 36.6% (434/1187) | 39.5% (286/724) | 32.0% (148/463) |
| 25–29.9 | 36.1% (428/1187) | 36.2% (262/724) | 35.9% (166/463) |
| 30–34.9 | 15.7% (186/1187) | 14.4% (104/724) | 17.7% (82/463) |
| ≥ 35 | 8.7% (103/1187) | 6.6% (48/724) | 11.9% (55/463) |
| Smoking | |||
| Active smoking | 13.8% (143/1040) | 12.6% (92/731) | 16.5% (51/309) |
| Former smoking | 15.1% (157/1040) | 13.5% (99/731) | 18.8% (58/309) |
| Nonsmoking | 71.2% (740/1040) | 73.9% (540/731) | 64.7% (200/309) |
| Comorbidities | |||
| Cardiovascular disease | 55.7% (1158/2079) | 49.9% (678/1358) | 66.6% (480/721) |
| Diabetes mellitus | 18.4% (385/2090) | 15.4% (210/1367) | 24.2% (175/723) |
| Pulmonary disease | 14.9% (307/2059) | 13.4% (179/1336) | 17.7% (128/723) |
| Hematological and/or oncological disease | 14.6% (305/2087) | 14.6% (200/1367) | 14.6% (105/720) |
| Neurological disease | 21.5% (411/1911) | 19.5% (245/1257) | 25.4% (166/654) |
| Kidney disease | 14.6% (305/2088) | 12.7% (173/1366) | 18.3% (132/722) |
| Other comorbidities* | 12.0% (243/2021) | 12.4% (164/1319) | 11.3% (79/702) |
| Pre-existing medication at day of positive SARS-CoV-2 test | |||
| ACE inhibitors | 18.1% (364/2008) | 16.2% (216/1332) | 21.9% (148/676) |
| AT-1-receptor antagonists | 17.2% (345/2000) | 16.3% (217/1330) | 19.1% (128/670) |
| Statins | 23.2% (335/1441) | 21.1% (200/946) | 27.3% (135/495) |
| Ibuprofen | 4.1% (78/1918) | 4.7% (60/1274) | 2.8% (18/644) |
| Pre-existing medication until three months before positive SARS-CoV-2 test | |||
| Any immunosuppressive medication | 10.3% (189/1841) | 11.0% (132/1202) | 8.9% (57/639) |
ACE inhibitors angiotensin-converting-enzyme inhibitor, AT-1-receptor antagonists angiotensin II type 1 (AT1) receptor antagonists. Other comorbidities—connective tissue disease, peptic ulcer disease, chronic liver disease, liver cirrhosis, organ transplantation, rheumatic disease, HIV/AIDS